SEC Filing Summary: Cerulean Pharma Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cerulean Pharma Inc. on August 17, 2016. The filing reports a material event under Item 8.01 (Other Events) regarding the announcement of top-line results from a Phase 2 clinical trial. Note: The request metadata references "Dare Bioscience, Inc.," but the filing text explicitly identifies the registrant as "Cerulean Pharma Inc."
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain a financial statement or quarterly results.
Material Changes and Clinical Results
The primary material event is the release of top-line results from a Phase 2 randomized, controlled, company-sponsored trial. The trial evaluated CRLX101 administered in combination with Avastin versus the investigator's choice of standard of care. The study population consisted of patients with relapsed renal cell carcinoma who had received two or three prior lines of therapy.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) by reference for full details on the trial results. The text explicitly states that information contained on websites referenced in the press release is not incorporated into this filing. No specific forward-looking guidance, risk factors, or management commentary beyond the trial announcement is provided within the body of this 8-K.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for specific efficacy and safety data from the CRLX101 trial.
- Confirm the registrant name is Cerulean Pharma Inc., not Dare Bioscience, Inc.
- Review the detailed statistical outcomes of the Phase 2 trial in the referenced exhibit to assess the drug's potential.
- Check subsequent filings for any financial impact or strategic changes resulting from these trial results.